Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 19
Gene Symbol: ABCA1
ABCA1
0.220 AlteredExpression disease BEFREE We investigated the effect of cilostazol on hepatic ABCA1 expression and hepatic steatosis in diet-induced obesity mice model. 26362727 2015
Entrez Id: 19
Gene Symbol: ABCA1
ABCA1
0.220 AlteredExpression disease BEFREE In this study, we determined the effects of IGF1 on ABCA1 expression in GH-deficient mice to clarify its effects on FL. 30130150 2018
Entrez Id: 19
Gene Symbol: ABCA1
ABCA1
0.220 Biomarker disease RGD Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. 15995177 2005
Entrez Id: 1244
Gene Symbol: ABCC2
ABCC2
0.200 Biomarker disease RGD Oatp2 and Mrp2 expression is decreased in fatty liver and may impair metabolism and biliary secretion of numerous xenobiotics. 16139386 2005
Entrez Id: 8714
Gene Symbol: ABCC3
ABCC3
0.200 Biomarker disease RGD Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. 17640958 2007
Entrez Id: 215
Gene Symbol: ABCD1
ABCD1
0.010 Biomarker disease BEFREE In summary, DMY likely modulates p62 and autophagy crosstalk with the Keap-1/Nrf2 pathway to alleviate liver steatosis and the inflammatory response in the pathological progression of ALD. 28419832 2017
Entrez Id: 64240
Gene Symbol: ABCG5
ABCG5
0.110 Biomarker disease HPO
Entrez Id: 64240
Gene Symbol: ABCG5
ABCG5
0.110 Biomarker disease BEFREE Decreases in other transport transcripts (ABCG5 & 8) provided a plausible mechanism for lipid accumulation, characterized by a treatment-related liver fatty change after PBDE-47 and PBDE mixture exposure. 30206662 2018
Entrez Id: 64241
Gene Symbol: ABCG8
ABCG8
0.100 Biomarker disease HPO
Entrez Id: 51099
Gene Symbol: ABHD5
ABHD5
0.120 GeneticVariation disease BEFREE Mutations in ABHD5 gene are associated with the onset of Chanarin-Dorfman syndrome (CDS), a rare autosomal recessive lipid storage disorder, characterized by non-bullous congenital ichthyosiform erythroderma (NCIE), hepatomegaly and liver steatosis. 24628803 2014
Entrez Id: 51099
Gene Symbol: ABHD5
ABHD5
0.120 Biomarker disease HPO
Entrez Id: 51099
Gene Symbol: ABHD5
ABHD5
0.120 Biomarker disease BEFREE CGI-58 knockdown in mice using antisense oligonucleotide (ASO) treatment also leads to severe hepatic steatosis as well as increased hepatocellular diacylglycerol (DAG) content, a well-documented trigger of insulin resistance. 23302688 2013
Entrez Id: 31
Gene Symbol: ACACA
ACACA
0.210 Biomarker disease RGD Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. 16485039 2006
Entrez Id: 31
Gene Symbol: ACACA
ACACA
0.210 Biomarker disease BEFREE Moreover, NI alleviated hepatic steatosis, possibly by significantly interacting with HFD to regulate lipid metabolism genes (including Srebp1c, Acc1, Fasn, Scd1, Cpt1a and Fabp5). 29309075 2018
Entrez Id: 32
Gene Symbol: ACACB
ACACB
0.200 Biomarker disease RGD Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. 16485039 2006
Entrez Id: 28976
Gene Symbol: ACAD9
ACAD9
0.100 Biomarker disease HPO
Entrez Id: 33
Gene Symbol: ACADL
ACADL
0.100 Biomarker disease HPO
Entrez Id: 34
Gene Symbol: ACADM
ACADM
0.100 Biomarker disease HPO
Entrez Id: 37
Gene Symbol: ACADVL
ACADVL
0.110 GeneticVariation disease BEFREE A combination of these data revealed that the liver steatosis in this case might have been caused by VLCAD deficiency based on genetic mutations of ACADVL. 25242572 2014
Entrez Id: 37
Gene Symbol: ACADVL
ACADVL
0.110 Biomarker disease HPO
Entrez Id: 59272
Gene Symbol: ACE2
ACE2
0.020 Biomarker disease BEFREE In vitro, Ang-(1-7)/ACE2 ameliorated hepatic steatosis, oxidative stress and inflammation in free fatty acid (FFA)-induced HepG2 cells, and what's more, Akt inhibitors reduced ACE2-mediated lipid metabolism. 26883384 2016
Entrez Id: 59272
Gene Symbol: ACE2
ACE2
0.020 Biomarker disease BEFREE This is the first time documented that ACE2 had a notable alleviating role in ER stress-induced hepatic steatosis and glucose metabolism via the IKKβ/NFκB/IRS1/Akt-mediated pathway. 30604460 2019
Entrez Id: 57007
Gene Symbol: ACKR3
ACKR3
0.010 Biomarker disease BEFREE In addition to LXRs, HDCA has been also shown to function as ligand for GPBAR1, a G protein coupled receptor for secondary bile acids whose activation represents a promising approach to liver steatosis. 28233865 2017
Entrez Id: 47
Gene Symbol: ACLY
ACLY
0.030 AlteredExpression disease BEFREE Additionally, hepatic SIRT2 overexpression decreased ACLY-3K acetylation and its protein level and alleviated hepatic steatosis in HF/HS diet-fed mice. 31197036 2019
Entrez Id: 47
Gene Symbol: ACLY
ACLY
0.030 Biomarker disease BEFREE ACLY is also a target against dyslipidaemia and hepatic steatosis, with a compound currently in phase 3 clinical trials<sup>4,5</sup>. 30944472 2019